Internal Medicine, Infectious Disease · Charlotte, NC
NPI
1417972886
Since 2006
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
1350 S Kings Dr
Charlotte, NC, 28207
Phone (704) 446-4490
Groups this clinician bills Medicare through
Medicare paid, 2024
$22K
1,946 services
Medicare patients, 2024
113
Average age 66
Drug cost, 2024
$4.6M
1,991 prescriptions
Company payments
-
None reported
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David A Weinrib was code 99232 (hospital e&m - subsequent), 87 times for 43 patients. In total David A Weinrib billed 1,946 services in 25 codes, and Medicare paid $22K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-07-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 87 | 43 | $60.15 | $5,233 |
| 99233 Hospital E&M - Subsequent | Facility | 51 | 30 | $90.48 | $4,615 |
| 99214 Office E&M - Established | Office | 49 | 27 | $77.17 | $3,781 |
| 99222 Hospital E&M - Initial | Facility | 28 | 26 | $97.71 | $2,736 |
| 99223 Hospital E&M - Initial | Facility | 19 | 19 | $133.56 | $2,538 |
By year: 2022 $43K for 6,575 services; 2023 $39K for 11,772 services; 2024 $22K for 1,946 services.
Medicare prescription drug claims, 2024
In 2024, the drug David A Weinrib prescribed most often to Medicare patients was Biktarvy (Bictegrav/Emtricit/Tenofov Ala), with 342 prescriptions and refills. In total David A Weinrib wrote 1,991 Medicare prescriptions that cost $4.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 342 | 346 | 37 | $1.4M |
| Tivicay Dolutegravir Sodium | 237 | 237 | 25 | $642K |
| Juluca Dolutegravir/Rilpivirine | 191 | 191 | 19 | $688K |
| Descovy Emtricitabine/Tenofov Alafenam | 145 | 145 | 16 | $334K |
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | 83 | 83 | Under 11 | $339K |
| Dovato Dolutegravir Sodium/Lamivudine | 77 | 77 | Under 11 | $239K |
| Darunavir Generic | 73 | 73 | Under 11 | $89K |
| Symtuza Darunavir/Cob/Emtri/Tenof Alaf | 73 | 73 | Under 11 | $356K |
| Valacyclovir Valacyclovir Hcl | 58 | 71 | 14 | $859 |
| Lamivudine Generic | 51 | 54 | Under 11 | $3,411 |
| Ritonavir Generic | 51 | 61 | Under 11 | $4,987 |
| Amlodipine Besylate Generic | 42 | 51 | Under 11 | $61.36 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 34 | 39 | Under 11 | $385 |
| Emtricitabine Generic | 30 | 31 | Under 11 | $6,942 |
| Triumeq Abacavir/Dolutegravir/Lamivudi | 30 | 30 | Under 11 | $115K |
Brand drugs: 1,295 claims; generic drugs: 696 claims.
Money and other things of value reported by the companies
No payments from drug or medical device companies to David A Weinrib were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.